Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03188263
Other study ID # STU00204710
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 5, 2017
Est. completion date December 31, 2019

Study information

Verified date December 2020
Source Northwestern University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary purpose of this pilot study is to test a novel head worn light device (Re-Timer®) as an intervention to improve glucose metabolism in people with prediabetes. The hypothesis is that morning light treatment will improve glucose metabolism. This is a pilot study and the data from this project will be used to develop a larger clinical trial.


Description:

This is a pilot study to determine whether light treatment can improve glucose metabolism in people with prediabetes. Individuals will be asked to complete a baseline session with one-week of at-home sleep monitoring followed by a 24-hour stay in the clinical research unit. During this stay, we will sample saliva in the evening to measure melatonin to estimate the timing of the internal biological clock ("circadian phase") and then we will perform a 3-hour oral glucose tolerance test in the morning to estimate markers of glucose metabolism, including insulin sensitivity. The participants will then be given a light device and instructed on its use. They will use the device for four weeks and visit our laboratory every week for a check-in. At the end of the four weeks, they will repeat the 24-hour stay in the clinical research unit.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date December 31, 2019
Est. primary completion date December 31, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 35 Years to 70 Years
Eligibility Inclusion Criteria: 34 subjects (50% female, age 40-65 y) Subjects will be: - Prediabetic (HbA1c 5.7% to <6.5%) - overweight or obese (BMI>25 kg/m2) - be free of moderate to severe obstructive sleep apnea (apnea-hypopnea index<30). The laboratory sessions will occur during women's follicular phase or women will be postmenopausal (=6 months since last menses). Subjects will be scheduled to participate = 1 month from travel outside the central time zone, and during a time with minimal special events. Exclusion Criteria: - Women who are pregnant, planning on becoming pregnant, or are breastfeeding. - Women on oral contraceptives or hormone replacement therapy will be excluded (alters OGTT and melatonin). - Men and women who have a child at home that does not sleep through the night will be excluded. - Adults unable to consent, individuals who are not yet adults (infants, children, teenagers), pregnant women, and prisoners are also excluded. - History of any form of diabetes, including use of diabetes medications - Age outside 35-70 years (we will not enroll anyone older than 70 years because of a reduced response to light). - Smokers - Shift workers - Failed urine drug test (drugs of abuse, nicotine) - Eye disease/photosensitizing medications - Sleep medications, diagnosed sleep disorders (history of treatment may affect glucose metabolism), - Daily beta-blocker, NSAID or melatonin use (confounds DLMO) - History of psychiatric disorders (confounds effect of light treatment, per relevant items from Mood Disorder, Psychotic Screening and Substance Use Disorders Modules of the Structured Clinical Interview for DSM-IV Axis I Disorders - Non-Patient Edition (SCID-IV/NP) to screen for schizophrenia, bipolar depression, substance abuse, suicidal ideation, obsessive compulsive disorder, PTSD), depressive symptoms using the Center for Epidemiologic Studies - Depression (CES-D) scale - Irregular menses - History of cardiovascular disease (excluding hypertension), endocrine, kidney, gastrointestinal or liver disorder, seizures, and cancer.

Study Design


Intervention

Other:
Bright Light
1 hour daily morning light treatment provided through a head-worn device for 4 weeks with the following settings: irradiance is 230 µW/m2 and lux is 500 lux.
Dim Light
1 hour daily morning light treatment provided through a head-worn device for 4 weeks with the following settings: irradiance in this dimmed is reduced from 230 µW/m2 to 3 µW/m2, and lux reduced from 500 lux to 7 lux

Locations

Country Name City State
United States Northwestern Memorial Hospital Chicago Illinois

Sponsors (2)

Lead Sponsor Collaborator
Northwestern University Rush University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Glucose Levels (Area-under-the-curve) Measured by Performance on Oral Glucose Tolerance Test (OGTT) The OGTT is a 3-hour procedure measuring blood glucose levels after the patient has consumed a 75-gram dextrose solution at -15 min, 0 min, 30 min, 60 min, 90 min, 120 min, and 180 min intervals. Total area-under-the-curve of glucose levels is calculated. Change from baseline to after 4 weeks of light treatment
Secondary Changes in Circadian Phase Measured by Dim Light Melatonin Onset (DLMO) The DLMO is measured via saliva samples collected during laboratory sessions. A sample is collected every half hour until bedtime starting 6.5 hours before habitual bedtime, and conducted in dim light setting to identify the point when melatonin starts being released. Change from baseline to after 4 weeks of light treatment.
See also
  Status Clinical Trial Phase
Recruiting NCT05354245 - Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL) N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Recruiting NCT03821961 - 18F-FDOPA PET/CT Imaging in Patients Undergoing Metabolic Surgery N/A
Completed NCT04303468 - Intervention With a GABA Supplement in Prediabetics N/A
Recruiting NCT06094231 - Treating Patients With Renal Impairment and Altered Glucose MetAbolism With TherapeutIc Carbohydrate Restriction and Sglt2-Inhibiton - a Pilot Study N/A
Completed NCT03675360 - Low-Carbohydrate Dietary Pattern on Glycemic Outcomes Trial N/A
Completed NCT01910051 - Explorative Assessment of Biomarkers in Overweight and Obese Subjects
Completed NCT03527368 - The Time-Restricted Intake of Meals Study N/A
Not yet recruiting NCT06453278 - (DDS) in India: a Screening Tool to Identify Prediabetes and Undiagnosed Type 2 Diabetes in Dental Settings
Completed NCT02899390 - Diabetes Prevention Program in Adults of the Yaqui Tribe of Hermosillo, Sonora at Risk of Diabetes N/A
Completed NCT03865342 - Prevention of Diabetes Using Mobile-enabled, Virtual Delivery of the National Diabetes Prevention Program N/A
Suspended NCT03240978 - Exercise Intervention for the Prevention of Prediabetes in Overweight Chinese N/A
Recruiting NCT01972113 - Vitamin K and Glucose Metabolism in Children at Risk for Diabetes (Vita-K 'n' Kids Study) N/A
Completed NCT01432509 - Prospective Follow-up of a Cohort of Pre-diabetics in the North of France (DiabeNord) N/A
Completed NCT01436916 - Oral Cholecalciferol in Prevention of Type 2 Diabetes Mellitus Phase 4
Completed NCT00990184 - Study to Evaluate the Effects of Colesevelam on Insulin Sensitivity and ß-Cell Function in Subjects With Impaired Fasting Glucose (Prediabetes) Phase 3
Completed NCT00886340 - A Lifestyle Change Program to Prevent Type 2 Diabetes Phase 2
Not yet recruiting NCT05658770 - Efficacy of Physical Exercise on Glucose Control in People With Prediabetes (GLYCEX) - Phase II N/A